Sam Brusco, Associate Editor11.23.21
Evoq Technologies earned FDA registration of the first in its family of smartphone-based biosensor products, the SmartERG platform to test retinal health.
Flashing a controlled light at the eye evokes an electrical-physiological retinal response that can reveal a great deal about retinal health. Delayed or reduced visual responses often signal diseases that lead to vision loss or blindness.
The Biophotomer smartphone product for dark adaptation impairment testing is currently a Class I medical device. Evoq intends to conduct clinical studies of the ophthalmic biosensor and specialty stimulators for submission as Class II medical devices next year.
“Our SmartERG Platform will offer a revolutionary delivery method for ophthalmic patient care; with the force multipliers of simple connection of patient to provider, cloud-based analytical services, and a perfect fit for artificial intelligence,” Evoq president Daniel Lindgren told the press. “We are paving the way for cost-effective screening for retinal disease, such as Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, and Glaucoma effectively using the same standard-of-care as equivalent legacy diagnostic devices, but at fraction of the cost, delivered worldwide.”
Lindgren also said Evoq is working with interested parties to assess positive impact on care delivery in the clinic, at the bedside, and at home. The firm is looking for licensing and partnership opportunities with medical device, pharmaceutical, and health delivery stakeholders.
Flashing a controlled light at the eye evokes an electrical-physiological retinal response that can reveal a great deal about retinal health. Delayed or reduced visual responses often signal diseases that lead to vision loss or blindness.
The Biophotomer smartphone product for dark adaptation impairment testing is currently a Class I medical device. Evoq intends to conduct clinical studies of the ophthalmic biosensor and specialty stimulators for submission as Class II medical devices next year.
“Our SmartERG Platform will offer a revolutionary delivery method for ophthalmic patient care; with the force multipliers of simple connection of patient to provider, cloud-based analytical services, and a perfect fit for artificial intelligence,” Evoq president Daniel Lindgren told the press. “We are paving the way for cost-effective screening for retinal disease, such as Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, and Glaucoma effectively using the same standard-of-care as equivalent legacy diagnostic devices, but at fraction of the cost, delivered worldwide.”
Lindgren also said Evoq is working with interested parties to assess positive impact on care delivery in the clinic, at the bedside, and at home. The firm is looking for licensing and partnership opportunities with medical device, pharmaceutical, and health delivery stakeholders.